Rallybio Corp
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $858,000 | $636,000 | — | — | — |
| Operating income | -$33.1M | -$60.5M | -$78.9M | -$67.9M | -$45.6M |
| Operating expenses | $33.9M | $61.1M | $78.9M | $67.9M | $45.6M |
| Cash from operations | -$29.8M | -$49.3M | -$60.3M | -$57.3M | -$45.5M |
| Capital expenditure | — | $0 | $12,000 | $54,000 | $333,000 |
| Free cash flow | — | -$49.3M | -$60.3M | -$57.3M | -$45.9M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $62.3M | $68.1M | $115.6M | $180.4M | $182.2M |
| Total liabilities | $4.3M | $6.5M | $9.4M | $11.1M | $6.6M |
Shares outstanding 5.3M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.